Left ventricular hypertrophy (LVH) can be regarded as an example of the evolution of cardiovascular disease en route to a bad outcome. Whilst LVH can also be regarded as an adaptive or compensatory response of the heart to increased blood pressure (BP) it is associated with many complications, such as sudden death, arrhythmias (including atrial fibrillation and ventricular arrhythmias), myocardial infarction, congestive heart failure and stroke. Of note, the frequency and severity of these complications are closer related to the degree of LVH than the level of the arterial pressure. Therefore, the effectiveness of anti-hypertensive treatment should not simply aim to reduce BP, but should also focus on the regression of hypertension-induced structural changes in the cardiovascular system, particularly LVH.
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Nevertheless, there is more to LVH than simply the elevation of BP. Other determinants of the development of LVH include hereditary and demographic factors such as age, gender, obesity, exogenous factors like dietary salt intake and alcohol, and neurohumoral factors such as the activity of the reninangiotensin-aldosterone system, the sympathetic system, insulin, parathyroid and other hormones. [1] [2] As hypertensive cardiovascular disease progresses, four pathophysiologic mechanisms are postulated to relate LVH with increased cardiovascular morbidity and mortality: 1 (i) impaired diastolic filling (reduction of early diastolic filling); (ii) myocardial ischaemia (impairment of coronary reserve); (iii) ventricular arrhythmias (which have been implicated in sudden death); and (iv) impaired myocardial contractility (resulting in dilatation of left ventricle and congestive heart failure).
Given the large impact of LVH on hypertensive morbidity and mortality, it is not surprising that there have been more than 1000 clinical and experimental studies in both animals and humans in the literature on the issue of LVH regression. The most critical issue in interpreting the results of studies of anti-hypertensive drugs and regression of LVH is the scientific quality and design. Most of the studies published to date have had serious limitations, including small size of patients, lack of blinding and validation of echocardiographic assessment, poor characterisation of study populations, and problems relating to the effects of prior antihypertensive treatment. The interpretation of the reported 'significant' reduction of LV mass is also a recurrent problem, in view of the known inter-and intra-study variability of echocardiographically measured LV mass. 3 Other important factors which may produce difficulties in the comparison between several studies are the individual profiles of drugs on 24-h control of BP and the ethnicity of study population, since black subjects may be less responsive to drugs that depress the renin-angiotensin system, such as betablockers and angiotensin-converting enzyme (ACE) inhibitors, when compared to whites. 4 The inclusion of elderly subjects in LVH regression trials is also problematic since it is probable that such patients have a high prevalence of isolated systolic hypertension, which is accompanied by relatively mild LVH. 5 Additionally, the baseline nutritional status of the studied population may be another important factor, since in the TOMHS study 6 nonpharmacological intervention was very successful in the placebo group, so that anti-hypertensive drugs could not have been expected to produce a large additional reduction in LVM. Recent data have identified dietary salt intake as a powerful, BP-independent determinant of left ventricular mass. 7 In a detailed review published in the Journal of Human Hypertension, Devereux and Dahlof 3 have proposed the ideal criteria for the design of an informative trial of LVH. They propose that all studies should be randomised and double-blind (except for non-pharmacological treatment), and should include comparisons between active agents or between an active agent and a placebo. These trials should also include both men and women, have a minimum duration of 6 months and should use an anatomically-validated echocardiographic or other imaging method. Studies dealing with pathophysiological or exploratory issues of a novel agent need to contain at least 20-30 subjects per treatment arm, whereas trials testing inter-agent differences should include an ethnically diverse population of at least 150-200 patients per treatment arm, with a minimum duration of 1 year. Finally, trials designed to see whether change in LV mass influences the prognosis should include at least 600 patients per treatment arm, with documentation of treatment and measurement of LV mass with an echocardiogram at baseline and at 1 year, with a trial duration of at least 4 years and adjustment for confounders. These criteria should be applied to designing future studies of LVH regression.
Nevertheless several meta-analyses have addressed the impact of anti-hypertensive treatment on LVH regression. For example, Dahlof et al 8 
and Cruickshank et al
9 have demonstrated differences amongst various classes of anti-hypertensive drugs on LVH regression. However, many studies included in both these meta-analyses were small and uncontrolled. With this reservation in mind, Dahlof et al 8 concluded that LVH regression was best achieved by the ACE inhibitors (16%), followed by diuretics (11%), calcium channel blockers (9%) and betablockers (8.5%). Cruickshank et al 9 also reported that reversibility of LVH was best with the ACE inhibitors, and significantly related to the length of time on treatment and the degree of fall of BP. The most recent meta-analysis by Schmieder et al 10 used strict criteria and included only 39 double-blind, randomised, controlled clinical studies with a parallel group design; after adjustment for confounders, ACE inhibitors decreased LVM index by 13.3% (95% confidence intervals (CI): 9.9-16.8%), whilst calcium channel blockers reduced LVM index by 9.3% (95% CI: 5.5-13.1%), beta-blockers by 5.5% (95% CI: 2.3-8.6%) and diuretics by 6.8% (95% CI: 3.0-10.7%). It was also shown that the decrease in the LVM index correlated with the change in systolic BP (SBP) (partial correlation coefficient r = 0.42, P Ͻ 0.001) and with the change in diastolic BP (DBP) (partial correlation coefficient r = 0.37, P Ͻ 0.01).
In the present issue of Journal of Human Hypertension, there is a study by Vyssoulis et al 11 which addresses the topic of LVM reduction in relation to the level of BP reduction. In this prospective study, the effect of the calcium antagonist, felodipine, in reducing LVM was compared in four treatment groups which were based upon the DBP level which was finally achieved (Ͻ80 mm Hg, 80-84 mm Hg, 85-89 mm Hg and 90-94 mm Hg). The patients had been followed-up for a period of 6 months using echocardiography. The overall reduction of LVM index was 12.3%, a figure which is slightly higher than the 9.3% found for calcium antagonists as a group in the meta-analysis by Schmieder et al. 10 In addition, the present study confirms the observations in the meta-analyses by Schmieder et al 10 and Cruickshank et al 9 that the greater the reduction in the DBP, the higher the reduction in the LVM index. Whilst meta-analyses have long been criticised for including a great many studies of different study design, patient population and inclusion criteria, the present prospective study represents a confirmation of what we had long suspected from results of the meta-analyses.
The available bulk of literature suggests that LVH regression is possible by most anti-hypertensive treatments, and the main question still to be answered is to what extent LVH regression, and the differences between anti-hypertensive agents, are translated to actually saving lives amongst hypertensives? Studies addressing prognosis and LVH regression which are conducted according to strict criteria as described by Devereux and Dahlof 3 are therefore needed, especially with new anti-hypertensive agents, such as the calcium antagonists. The latter class of drugs have been subject to much controversy, with questions raised over its safety and efficacy, although much of the alarm was raised over cross-sectional studies and short-acting dihydropyridine calcium antagonists. 12 Recent studies, such as the DHCCP project 13 and the large SYST-EUR study 14 that used long-acting calcium antagonists have provided reassuring data on the safety and benefits in reducing stroke and mortality. However, there is evidence that the calcium antagonists may be less beneficial in high risk subgroups, such as diabetics with hypertension, when compared to agents such as the ACE inhibitors. 15 Large prognostic studies of anti-hypertensive agents, comparing 'new' and 'old or traditional' agents, such as the ALLHAT and ASCOT studies are in progress, but will not report until the new millenium.
